STOCK TITAN

Orthofix Medical (OFIX) Stock News, Nov 2024-Jun 2025

OFIX NASDAQ

Orthofix Medical Inc. reports developments across its orthopedic and spine medical technology portfolio. The company provides spinal implants, therapeutic solutions, limb reconstruction systems, biologics and enabling technologies, including the 7D FLASH Navigation System, for complex musculoskeletal conditions.

Recurring OFIX news includes quarterly results, guidance, product launches and commercial execution in Spine and Orthopedics. Company updates also cover pediatric limb reconstruction offerings such as FITBONE, planning software such as OrthoNext, the TRUELOK Elevate system, spine leadership realignment, distributor transitions, biologics activity and the discontinued M6 artificial disc product lines.

Rhea-AI Summary
Orthofix Medical Inc. (NASDAQ:OFIX) has announced the global commercial launch of the TrueLok Elevate Transverse Bone Transport (TBT) System, the first FDA-cleared device in the U.S. for TBT procedures aimed at limb preservation. The system targets bony and soft tissue deformities, particularly diabetic ulcers. With diabetes projected to affect 700 million people globally by 2045 and over 160,000 annual diabetic-related amputations in the U.S., the market opportunity is estimated at $1.2 billion. The device has shown promising results during limited market release with over 130 procedures completed globally. Notably, diabetic foot ulcer patients who undergo amputation face a 57% five-year mortality rate and lifetime healthcare costs exceeding $640,000, making TrueLok Elevate a potentially cost-effective limb-saving solution.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-3.75%
Tags
none
-
Rhea-AI Summary

Orthofix Medical Inc. (NASDAQ:OFIX) reported its Q1 2025 financial results with net sales of $193.6 million, representing a 2.7% increase year-over-year. The company posted a net loss of $(53.1) million, or $(1.35) per share. Notable performance includes Bone Growth Therapies sales growth of 5%, Global Orthopedics achieving 11% constant currency growth, and U.S. Spine Fixation growth of 4%.

The company updated its 2025 guidance, now expecting net sales between $808-816 million, while reaffirming non-GAAP adjusted EBITDA guidance of $82-86 million. Pro forma adjusted EBITDA for Q1 was $11.4 million, showing a 200 basis points margin expansion. The company is executing a commercial channel optimization strategy, though this has caused some softness in Biologics and Spine Fixation segments.

Cash position stood at $60.5 million as of March 31, 2025, down from $85.7 million in December 2024, primarily due to annual bonus payments and commissions.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-10.93%
Tags
-
Rhea-AI Summary

Orthofix Medical (NASDAQ:OFIX) has scheduled the release of its first quarter 2025 financial results for Tuesday, May 6, 2025, before the market opens. The company will host a conference call and webcast at 8:30 am Eastern Time on the same day to discuss the results.

Participants can join the conference call by dialing (888) 596-4144 in the U.S. and (646) 968-2525 from other locations, using conference ID 7524113. The webcast and earnings release will be available at ir.Orthofix.com.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.52%
Tags
conferences earnings
Rhea-AI Summary

Orthofix Medical Inc. (NASDAQ:OFIX) has received both FDA 510(k) clearance and European CE Mark for its TrueLok™ Elevate Transverse Bone Transport (TBT) System, marking a significant advancement in limb preservation treatment.

The system, currently in market release in the U.S. and select international markets, addresses bony and soft tissue deformities, including diabetic foot ulcers and nonhealing wounds. It is the first FDA-cleared dedicated system for TBT procedures, enabling surgeons to create and gradually distract bone segments in the tibia.

This innovation targets a $1.2 billion market opportunity, addressing the over 160,000 annual diabetic-related amputations in the U.S. Studies show patients with diabetic foot ulcers who undergo amputation face a 57% five-year mortality rate and lifetime healthcare costs exceeding $640,000 for amputation-related care.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.90%
Tags
none
-
Rhea-AI Summary

Orthofix Medical (NASDAQ:OFIX) has appointed Vickie Capps to its Board of Directors, effective March 11, 2025. This strategic addition expands the board to ten members, bringing diverse expertise in global business operations, strategic development, and corporate finance.

Capps, a Certified Public Accountant with a B.S. in business administration from San Diego State University, brings significant experience from her role as former CFO of DJO Global, Inc. She currently serves on multiple boards, including Amedisys, Inc., Janux Therapeutics, Inc., Enable Injections, Inc., and Breg, Inc. She is also a member of the Senior Advisory Board of Consonance Capital Partners.

The appointment aligns with Orthofix's strategic transformation aimed at delivering profitable growth and sustainable shareholder value in the medical technology sector, focusing on musculoskeletal pathologies.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.99%
Tags
management
-
Rhea-AI Summary

Orthofix Medical (NASDAQ:OFIX) has announced its participation in the 37th Annual Roth Conference in Dana Point, CA. The company's management team is scheduled to deliver a presentation on Monday, March 17, 2025, at 8:00 AM Pacific Time.

Investors and interested parties can access both the live and archived versions of the presentation through the 'Events & Presentations' section on Orthofix's investor relations website at ir.orthofix.com. The company also maintains regular updates of important investor information in the 'Investors' section of their corporate website at www.orthofix.com.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-2.30%
Tags
conferences
Rhea-AI Summary

Orthofix Medical reported record fourth quarter 2024 net sales of $215.7 million, an 8% increase from Q4 2023. U.S. Spine Fixation sales grew by 12%, and Bone Growth Therapies (BGT) sales hit a record $63.9 million, a 9% increase. Global Orthopedics sales rose by 18% to $35.8 million. Despite these gains, the company reported a net loss of $(29.1) million and EPS of $(0.75). Non-GAAP adjusted EBITDA was $23.9 million, up 22% from Q4 2023. For the full year 2024, net sales reached $799.5 million, a 7% increase, with a net loss of $(126.0) million and EPS of $(3.30). Non-GAAP adjusted EBITDA for the year was $67.4 million, a 46% increase. Orthofix discontinued its M6 artificial disc product lines to focus on more profitable growth areas. The company provided 2025 guidance, expecting net sales between $818 million to $826 million and adjusted EBITDA between $82 million to $86 million. Free cash flow is expected to be positive for 2025.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-3.53%
Tags
-
Rhea-AI Summary

Orthofix Medical (NASDAQ:OFIX) has announced its participation in the Canaccord Genuity 2025 Musculoskeletal Conference in San Diego. The company's management will deliver a presentation on Monday, March 10, 2025, at 9:00 AM Pacific Time.

Investors and interested parties can access both the live and archived versions of the presentation through the 'Events & Presentations' section on Orthofix's investor relations website at ir.orthofix.com. The company regularly posts important investor information on its website www.orthofix.com under the 'Investors' section, and encourages current and potential investors to monitor this platform for updates.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.11%
Tags
conferences
-
Rhea-AI Summary

Orthofix Medical (NASDAQ:OFIX) has scheduled the release of its fourth quarter and full-year 2024 financial results for Tuesday, February 25, 2025, before the market opens. The company will host a conference call and webcast at 8:30 am Eastern Time on the same day to discuss the results.

Participants can join the conference call by dialing (888) 596-4144 in the U.S. and (646) 968-2525 from other locations, using the event passcode 5184023. The webcast and earnings release will be available on the company's investor relations website at ir.Orthofix.com.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.20%
Tags
conferences earnings
Rhea-AI Summary

Orthofix Medical (NASDAQ:OFIX) has announced its leadership team's participation in two upcoming investor conferences. President and CEO Massimo Calafiore and CFO Julie Andrews will attend the Stifel 2024 Healthcare Conference in New York on November 18, 2024, with a fireside chat at 8:35 AM ET, and the Stifel MedTech Madness 2024 Annual West Coast Bus Tour in Laguna Beach on December 9, 2024, with a fireside chat at 8:00 AM PT. Live webcasts and replays will be available on the Orthofix website's Investors section.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-3.85%
Tags
conferences

FAQ

What is the current stock price of Orthofix Medical (OFIX)?

Orthofix Medical (OFIX) last closed at $6.07.

What is the market cap of Orthofix Medical (OFIX)?

The market cap of Orthofix Medical (OFIX) is approximately $247.4M.